Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has issued an update.
Infant Bacterial Therapeutics is advancing the registration process for its drug candidate IBP-9414 in the US and Europe, with ongoing communications with the FDA and EMA. The company is nearing completion of the necessary documentation and expects to finalize the manufacturing validation soon, positioning itself for potential market authorization and addressing unmet medical needs for premature infants.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company based in Stockholm, specializing in developing and commercializing drugs for diseases affecting premature babies. The company focuses on using live bacteria as active substances, with its primary drug candidate being IBP-9414, a bacterial strain found in human breast milk. IBT’s portfolio also includes other drug candidates targeting conditions such as gastroschisis, retinopathy of prematurity, and vancomycin-resistant enterococci.
YTD Price Performance: 16.79%
Average Trading Volume: 11,880
Technical Sentiment Signal: Buy
Current Market Cap: SEK843.3M
See more data about IBT.B stock on TipRanks’ Stock Analysis page.